BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14766252)

  • 1. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
    Markman J; Zanotti K; Webster K; Belinson J; Peterson G; Kulp B; Markman M
    Gynecol Oncol; 2004 Feb; 92(2):592-5. PubMed ID: 14766252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
    Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
    Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
    Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
    Nagao S; Okimoto N; Hongo A; Mizutani Y; Kodama J; Yoshinouchi M; Hiramatsu Y; Kudo T
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
    Kietpeerakool C; Suprasert P; Srisomboon J
    J Med Assoc Thai; 2005 Mar; 88(3):301-6. PubMed ID: 15962635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.
    Sharma S; Rezai K; Driscoll D; Odunsi K; Lele S
    Gynecol Oncol; 2006 Oct; 103(1):181-5. PubMed ID: 16574203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
    Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
    Morabito F; Irrera G; Oliva E; Console G; Martino M; Pucci G; Messina G; Barbaro P; Palazzo S; Iacopino P
    Bone Marrow Transplant; 2001 Nov; 28(9):883-8. PubMed ID: 11781650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.
    Vergote I; Debruyne P; Kridelka F; Berteloot P; Amant F; Honhon B; Lybaert W; Leunen K; Geldhof K; Verhoeven D; Forget F; Vuylsteke P; D'Hondt L; Huizing M; Van den Bulck H; Laenen A
    Gynecol Oncol; 2015 Aug; 138(2):278-84. PubMed ID: 26049123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
    Pfisterer J; du Bois A; Wagner U; Quaas J; Blohmer JU; Wallwiener D; Hilpert F;
    Gynecol Oncol; 2004 Mar; 92(3):949-56. PubMed ID: 14984965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-colony stimulating factors for secondary prevention of leucopenia in patients receiving chemotherapy.
    Lowathanasirikul J; Manusirivithaya S; Tangjitgamol S; Leelahakorn S
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S47-53. PubMed ID: 17726809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.